Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most serious risk statements align with the provided FDA label sections (renal, hepatic, GI hemorrhage). However, the response includes several efficacy/administration/monitoring and interaction claims that are not fully supported by the provided label excerpts and may be overly generalized.
Category Scores
Accurate Statements
Serious risks of deferasirox can include effects on the kidneys.
Supported by Section 5.1: 'can cause acute kidney injury including renal failure requiring dialysis that has resulted in fatal outcomes.'
Serious risks of deferasirox can include effects on the liver.
Supported by Section 5.2: 'can cause hepatic injury, fatal in some patients' and 'Acute liver injury and failure, including fatal outcomes, have occurred...'
Serious risks of deferasirox can include effects on the liver.
Supported by Section 5.2 pediatric liver failure statements.
Common concerns with deferasirox include changes in lab tests.
Supported implicitly by Section 5.2 requiring transaminases/bilirubin monitoring and considering dose modifications for elevations; and Section 5.1 monitoring renal function markers.
If lab values change during deferasirox treatment, clinicians may reduce the dose.
Supported by Section 5.2: 'Consider dose modifications or interruption of treatment for severe or persistent elevations.' and Section 5.1: 'Dose reduction or interruption may be considered if abnormalities occur...'
If lab values change during deferasirox treatment, clinicians may interrupt treatment.
Supported by Section 5.2: 'Consider dose modifications or interruption...' and Section 5.1: 'Dose reduction or interruption may be considered...'
People with known kidney problems typically need extra caution when using deferasirox.
Supported by Section 5.1: 'Preexisting renal disease... may increase the risk...' and 'Monitor renal function more frequently in patients with preexisting renal disease or decreased renal function.'
People with known liver problems typically need extra caution when using deferasirox.
Supported by Section 5.2: 'Avoid the use... in patients with severe (Child-Pugh C)...' and 'Reduce the starting dose in patients with moderate...' plus 'Patients with mild... or moderate... may be at higher risk...'
Unsupported Statements
Deferasirox is an oral medicine used to treat iron overload in people who have too much iron in the body.
No supporting label excerpt provided for indication/approved uses.
Deferasirox works by binding iron.
Mechanism not supported by the provided label excerpts.
After binding iron, the body can remove it mainly through excretion.
Excretion route not supported by the provided label excerpts.
Deferasirox is taken as a tablet by mouth once daily.
The provided drug verification states oral granules; dosing frequency/schedule for this formulation is not supported by the provided excerpts.
Clinicians adjust deferasirox treatment over time to keep iron under control.
General titration concept is not explicitly supported by the provided excerpts (label excerpts focus on renal/hepatic/GI precautions and monitoring).
Common side effects or concerns with deferasirox include gastrointestinal upset.
GI upset examples (e.g., nausea/diarrhea/abdominal pain) are mentioned in Section 6.1 as frequent adverse reactions, but the claim is not clearly tied to 'common' and does not specify the label’s listed GI symptoms; partial/overgeneralized.
Monitoring blood counts and organ function is typically part of routine care for patients on deferasirox.
The provided excerpts specify renal and hepatic monitoring (eGFR, serum electrolytes/urinalysis, transaminases/bilirubin) but do not mention blood counts as a routine requirement.
Patients on deferasirox generally need periodic blood tests to track iron levels.
The excerpts mention 'Monitor serum ferritin monthly' but do not explicitly frame this as 'tracking iron levels' via 'blood tests' in general terms (though ferritin is a blood test, the claim is slightly overgeneralized beyond the provided wording).
Patients on deferasirox generally need periodic blood tests to monitor kidney and liver function.
Renal monitoring is explicitly required, but the excerpt does not explicitly state 'periodic blood tests' for kidney and liver function (it includes urinalysis/eGFR and specific lab schedules for transaminases/bilirubin).
People with known liver problems typically need extra caution when using deferasirox.
Partially supported, but the 'typically need extra caution' phrasing is more general than the label’s specific Child-Pugh guidance; included here only if considered beyond provided explicit actions.
Drug interactions are a key concern for iron chelation therapy.
The provided excerpts mention interaction risk specifically with ulcerogenic/hemorrhagic potential drugs, but do not support the broad statement that drug interactions are a 'key concern' overall.
Clinicians review other medicines before starting iron chelation therapy.
Not explicitly supported by the provided excerpts.
Deferasirox chelates iron for removal.
Chelation/iron removal mechanism not supported by the provided excerpts.
Other iron chelators such as deferoxamine and deferiprone differ in route, dosing schedule, and side-effect profile.
Not supported by the provided excerpts.
Clinicians choose between iron chelators based on patient needs and monitoring results.
Not supported by the provided excerpts.
Contradictions
Low
AI Statement
Deferasirox is taken as a tablet by mouth once daily.
Label Reference
Drug form in provided context is oral granules; label excerpts do not state tablet once daily dosing.
Important Omissions
Specific contraindication threshold and dosing modifications for renal impairment (e.g., eGFR <40 mL/min/1.73 m^2 contraindication; 50% starting dose reduction for eGFR 40-60) and detailed monitoring schedule (weekly first month, then at least monthly; transaminases/bilirubin every 2 weeks first month).
Importance:
Moderate
The provided excerpts also include instructions about interrupting therapy during volume depletion (vomiting/diarrhea/decreased oral intake) and correcting fluid deficits; these were not captured in the response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While major serious risks (kidney injury requiring dialysis, hepatic injury/failure, GI hemorrhage/deaths) were aligned with the label excerpts, several management-related and administration/general monitoring claims were either not supported or overly generalized, which could lead to inaccurate expectations about monitoring (e.g., blood counts) or dosing form/frequency.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple non-supported/generalized claims (indication/mechanism/excretion, tablet once-daily dosing, broad interaction/selection statements, and blood counts monitoring) are not supported by the provided label excerpts.
Suggested Improvement
Limit claims to what is present in the supplied prescribing-information excerpts (5.1, 5.2, 5.3 and 6.1/6.2), including the specific renal/hepatic monitoring schedule, Child-Pugh guidance, and the specific drug-interaction risk framing (ulcerogenic/hemorrhagic potential drugs).